Why Dr. Reddy's Laboratories Limited’s (RDY) Stock Is Up 5.18%
As of Thursday, September 17, Dr. Reddy's Laboratories Limited’s RDY share price has surged by 5.18%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | RDY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,426.6 | $486.8 | 80% |
|
| Shares Out (Mil) | 8.7 | 42.8 | 19% |
|
| Institutional Ownership | 68.7% | 81.8% | 42% |
|
| Float (Mil) | 600.1 | 44.5 | 87% |
|
| Beta | 0.25 | 0.72 | 15% |
|
| Avg Daily Volume (000s) | 3,371 | 275 | 88% |
|
| Price Change (52-week) |
(5.7%) | 55.6% | 48% |
|
| Growth | RDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.7% | 6.4% | 44% |
|
| Net Income (5yr) | 14.2% | (2.0%) | 62% |
|
| EPS (5yr) | 14.1% | 15.0% | 54 |
|
| Dividends (5yr) | 4.5% | 0.0% | 56% |
|
| Cash Flow (5yr) | (43.0%) | (15.1%) | 10% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,440 | $392 | 69% |
|
| Net Income (TTM) (Mil) | $292 | ($11) | 72% |
|
| EPS (TTM) | $0.351 | ($0.700) | 51% |
|
| Operating Cash Flow (TTM) (Mil) | $322 | ($7) | 65% |
|
| Net Cash Flow (TTM) (Mil) | $39 | $4 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $122 | $6 | 46% |
|
| Enterprise Value (Q1) (Mil) | $11,313 | $494 | 76% |
|
| Valuation | RDY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.85 | 2.17 | 66% |
|
| P/E | 39.3 | 17.3 | 79% |
|
| Dividend Yield | 0.6% | 0.0% | 63% |
|
| PEG (5yr hist) | 2.8 | 1.2 | 77% |
|
| Ratios | RDY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 49.5% | 69.4% | 61% |
|
| Net Margin | 8.5% | 3.3% | 58% |
|
| ROA | 4.8% | (22.0%) | 70% |
|
| ROE | 7.2% | (20.6%) | 48% |
|
| Liabilities to Assets | 32.2% | 32.2% | 23% |
|
| F-Score | 6 | 3 | 67% |
|
Dr. Reddy's Laboratories Limited did not pass any screens on 10/27/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors